UCLA IRB #05-12-061 "A PHASE I STUDY OF VORINOSTAT (SUBEROYLANILIDE HYDROXAMI

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 具体目标： 主要目标 目的：确定恶性胶质瘤患者联合替莫唑胺的最大耐受量(MTD)。 目的：确定恶性胶质瘤患者联合替莫唑胺的最大耐受量(MTD)。 [目的]研究止血药(SAHA)与替莫唑胺联合应用的安全性。 次要目标 [目的]研究伏立宁(SAHA)与替莫唑胺合用的药代动力学。 目的：通过客观疗效评价伏立宁(SAHA)与替莫唑胺联合应用的疗效。 探索性目标 [目的]探讨治疗反应与肿瘤分子表型的关系。 [目的]探讨伏立诺(SAHA)对外周血单个核细胞组蛋白乙酰化状态的影响。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. SPECIFIC AIMS: Primary Objectives ¿ To define the maximum tolerated dose (MTD) of vorinostat in combination with temozolomide in patients with malignant gliomas. ¿ To define the maximum tolerated dose (MTD) of vorinostat in combination with temozolomide in patients with malignant gliomas. ¿ To characterize the safety profile of vorinostat (SAHA) in combination with temozolomide. Secondary Objectives ¿ To characterize the pharmacokinetics of vorinostat (SAHA) in combination with temozolomide. ¿ To determine efficacy of vorinostat (SAHA) in combination with temozolomide as measured by objective response. Exploratory Objectives ¿ To explore the association of response to treatment to the molecular phenotype of the tumor. ¿ To assess the effects of vorinostat (SAHA) on histone acetylation status in peripheral mononuclear cells.